Show simple item record

dc.contributor.advisorGürsel, İhsanen_US
dc.contributor.authorErtuna, Yusuf İsmailen_US
dc.date.accessioned2016-01-08T20:18:19Z
dc.date.available2016-01-08T20:18:19Z
dc.date.issued2014
dc.identifier.urihttp://hdl.handle.net/11693/18328
dc.descriptionAnkara : The Department of Molecular Biology and Genetics and the Graduate School of Engineering and Science of Bilkent University, 2014.en_US
dc.descriptionThesis (Master's) -- Bilkent University, 2014.en_US
dc.descriptionIncludes bibliographical references leaves 96-106.en_US
dc.description.abstractHepatocellular carcinoma (HCC) is the seventh most common cancer type worldwide, and ranked third place among cancer-related deaths within both sexes. As in many solid tumors, HCC shelters a cancer stem cell subpopulation, and is held responsible for the resistance developed during chemo-and-radio-therapy of HCC. The only option to cure HCC is liver transplantation, which is the bottleneck to provide a remedy to patients due to limited availability. Understanding the stem cell behavior of HCC would critically contribute to develop effective eradication strategies. In this study, a panel of 17 HCC cell lines was evaluated for their CSC status. Of these cell lines, six of them were determined to be positive for CD133 expression, a cardinal CSC marker. Next, HepG2, Huh7 and Hep3B-TR, (a desensitized TGF-beta-1 receptor clone) were selected and Notch activity vs. CSC fraction was investigated by analyzing CD133+/EpCAM+ levels. Our results revealed that DAPT (a notch inhibitor) led to a drop in CD133+/EpCAM+ levels in HepG2 and Huh7 by half, but not in Hep3B-TR cells, implicating a possible TGFβ1R involvement on CSC generation/maintenance. Treatment of cells with a notch ligand, Jagged-1, however, had little or no positive effect on CD133+/EpCAM+ expressions in all tested cells. Additionally, HCC cells' response to different TLR ligands and the resulting transcript expressions of TLRs were investigated by PCR. Of note, TLRs are widely used in immunotherapy of cancers. Here we aimed to combine Notch inhibitor along with selected TLR ligand, thereby improving tumor clearance in athymic mice xenografted with HCC. We found that in three selected cell lines upon TLR2 ligand stimulation, TLR5 and TLR7 were highly upregulated. Afterwards, treating these HCC cell lines with these ligands we observed that TLR3, TLR7/8 and TLR9 levels were activated. In the final part of this study, tumor-bearing mice with Huh7, were subjected to a combination therapy with TLR ligands +/- DAPT. We demonstrated that combination therapy comprising TLR3, 7/8 and 9 ligands and DAPT (only two injections, a week apart) induced significant tumor regression.en_US
dc.description.statementofresponsibilityErtuna, Yusuf İsmailen_US
dc.format.extentxvii, 112 leaves, charts, plates, illustrationsen_US
dc.language.isoEnglishen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectCancer stem cellsen_US
dc.subjectNotch signaling pathwayen_US
dc.subjectToll-like receptorsen_US
dc.subjectCD133en_US
dc.subjectEpCAMen_US
dc.subjectTherapyen_US
dc.subject.lccWI735 .E77 2014en_US
dc.subject.lcshCarcinoma, Hepotocellular.en_US
dc.subject.lcshCancer cells.en_US
dc.titleContribution of notch signaling on HCC stem cell status and utilizing TLR agonists and notch inhibition to improve HCC theraphyen_US
dc.typeThesisen_US
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.publisherBilkent Universityen_US
dc.description.degreeM.S.en_US
dc.identifier.itemidB148430
dc.embargo.release2016-09-22


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record